➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Baxter
Colorcon
Merck
Medtronic
Mallinckrodt
Dow

Last Updated: June 15, 2021

DrugPatentWatch Database Preview

Drugs in Development Information for pyrotinib


Email this page to a colleague

« Back to Dashboard

What is the drug development status for pyrotinib?

pyrotinib is an investigational drug.

There have been 82 clinical trials for pyrotinib. The most recent clinical trial was a Phase 1 trial, which was initiated on July 1st 2016.

The most common disease conditions in clinical trials are Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, and Breast Diseases. The leading clinical trial sponsors are Jiangsu HengRui Medicine Co., Ltd., Fudan University, and Sun Yat-sen University.

There are six US patents protecting this investigational drug and fifty international patents.

Recent Clinical Trials for pyrotinib
TitleSponsorPhase
TKIs vs. Pertuzumab in HER2+ Breast Cancer Patients With Active Brain Metastases (HER2BRAIN)Peking University International HospitalPhase 2
TKIs vs. Pertuzumab in HER2+ Breast Cancer Patients With Active Brain Metastases (HER2BRAIN)Sun Yat-sen UniversityPhase 2
TKIs vs. Pertuzumab in HER2+ Breast Cancer Patients With Active Brain Metastases (HER2BRAIN)Zhejiang UniversityPhase 2

See all pyrotinib clinical trials

Clinical Trial Summary for pyrotinib

Top disease conditions for pyrotinib
Top clinical trial sponsors for pyrotinib

See all pyrotinib clinical trials

US Patents for pyrotinib

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
pyrotinib   Get Started Free Method for preparing pharmaceutical composition comprising quinoline derivative or salt thereof Jiangsu Hengrui Medicine Co., Ltd. (Lianyungang, Jiangsu, CN)   Get Started Free
pyrotinib   Get Started Free Method for preparing tyrosine kinase inhibitor and derivative thereof Jiangsu Hengrui Medicine Co., Ltd. (Lianyungang, Jiangsu, CN)   Get Started Free
pyrotinib   Get Started Free Method for preventing or treating tumor diseases with a combination of tyrosine kinase inhibitor and CDK4/6 inhibitor JIANGSU HENGRUI MEDICINE CO., LTD. (Jiangsu, CN) SHANGHAI HENGRUI PHARMACEUTICAL CO., LTD. (Shanghai, CN)   Get Started Free
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Dow
McKesson
Mallinckrodt
Johnson and Johnson
AstraZeneca
Harvard Business School

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.